Back to Studies

P1094 / Evaluation of the use 3TC

Evaluation of 3TC or FTC Monotherapy Compared to Continuing HAART as a Bridging Antiretroviral Strategy in Persistently Non-Adherent Children, Adolescents, and Young Adults Who Are Failing HAART and Have the M184V Resistance Mutation

Study Status

Concluded

DAIDS Number

11769

Clinical Trials Link

Study Chair

Study Vice-Chair

DAIDS Medical Officer

NICHD Medical Officer

DAIDS Clinical Representative

Data Manager

Laboratory Data Manager (LDM)

Laboratory Specialist

Laboratory Technologist

Protocol Pharmacist

Virologist

Westat Representative

Abstracts

Equipoise is in the eye of the beholder: Issues in clinical trial design and implementation when there are regional differences in perceived equipoise

Study

P1094

Immunologic Outcomes of a Randomized Controlled Trial of 3TC/FTC Monotherapy Compared to Continuing Failing cART as a Bridging Antiretroviral Strategy in Persistently Non-adherent HIV-infected Youth Harboring the M184V Resistance Mutation: Results from the IMPAACT P1094 Trial

Conference

Pediatric Meeting and AIDS Conference

Study

P1094

Authors

Allison Agwu, Meredith Warshaw, George Siberry, Ann Melvin, Elizabeth McFarland, Andrew Wiznia, Lee Fairlie, Sandra Boyd, Hans Spiegel, Elaine Abrams, Vincent Carey for the P1094 Study Team